Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06058234 · ClinicalTrials.gov registry record
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
A clinical trial of Mild Alzheimer's Disease and Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, sponsored by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group.
- Recruiting
- Registry status
- 8,680
- Enrollment target
- 1
- Study location
NCT06058234: Recruiting study of Mild Alzheimer's Disease and Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, sponsored by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group.
NCT06058234 is a study of Mild Alzheimer's Disease and Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease that is actively recruiting participants, run by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group. The registered enrollment target is 8,680 participants, above the 77-participant average among 3 other Mild Alzheimer's Disease trials with a reported enrollment target (11173% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06058234, a study of Mild Alzheimer's Disease and Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, is actively recruiting participants, sponsored by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group.
- RECRUITING
- Registry status
- 8,680 participants
- Enrollment target
- 1
- Study location
Study Summary
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Primary Outcome
Cognition measured by the Montreal Cognitive Assessment (MoCA©) (score ranges from 0 to 30; higher scores are generally better).
Conditions Studied
Interventions
- DRUG Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Study Locations (1)
Maryland
- Centers for Medicare and Medicaid Services - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,680 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2029-06-30 |
What NCT06058234 shows while recruiting
NCT06058234 is an observational study that tracks outcomes without assigning an intervention. Its 8,680 participants enrollment target places it among the larger protocols in the corpus, above the 77-participant average among 3 other Mild Alzheimer's Disease trials with a reported enrollment target (11173% higher).
The record links to 2 conditions, with Mild Alzheimer's Disease appearing as the primary indexed condition, and to 1 intervention - of which Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease is the first listed.
NCT06058234 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06058234 about?
NCT06058234 is a clinical study titled "Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study". The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies D...
What is the current status of trial NCT06058234?
This trial is currently recruiting. The enrollment target is 8,680 participants. The study started on 2023-07-06. Estimated completion is 2029-06-30.
What conditions does trial NCT06058234 study?
This clinical trial studies the following conditions: Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease.
What interventions are being tested in trial NCT06058234?
The interventions under investigation include: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (DRUG).
Who is sponsoring clinical trial NCT06058234?
This trial is sponsored by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06058234 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease
RECRUITING · NA
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Early Detection of Mild Cognitive Impairment in Individual Patients
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT06098079 · 8,600 participants · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI